Bonjour Holdings Limited announced after market close on 17 March 2026 that it has signed a Subscription Agreement with independent third-party investor Mr. Ko Kin Hang for the issuance of 86.00 million new shares under its existing general mandate.

Key terms • Issue size and price: 86.00 million shares at HK$0.070 each, raising gross proceeds of HK$6.02 million and estimated net proceeds of HK$5.92 million. • Pricing: The subscription price represents a 19.54% discount to the 17 March closing price of HK$0.087 and a 17.84% discount to the five-day average of HK$0.0852. • Mandate capacity: The general mandate, approved on 28 November 2025 for up to 336.06 million shares, still has room after 108.57 million shares were issued in February 2026; thus no additional shareholder approval is required. • Listing: An application will be filed with the Stock Exchange for listing and dealing approval of the new shares.

Capital structure impact • Current issued shares: 1.79 billion. • Post-placement issued shares: 1.87 billion. • Dilution: New shares will account for 4.59% of enlarged share capital. • Major shareholder Mr. Chen Jianwen’s stake will decline from 50.33% to 48.02%. • The subscriber will hold 4.59% post-completion; he currently holds no shares.

Use of proceeds (net HK$5.92 million) 1. Staff costs: HK$2.00 million 2. Rental expenses: HK$1.30 million 3. Debt repayment: HK$1.62 million 4. Professional fees: HK$1.00 million

Recent fund-raising track record • February 2026: 108.57 million shares issued at HK$0.105, netting HK$11.30 million; HK$2.06 million remains to be deployed by end-April 2026. • September–October 2025: Rights issue and placing raised approximately HK$97.00 million, fully utilised.

Rationale Management positions the placement as a swift, non-debt funding option to reinforce liquidity and support working-capital needs amid ongoing expansion in beauty, healthcare, lifestyle and 3C product distribution. The board views the terms as fair and in the interests of shareholders.

Timetable and conditions Completion is contingent upon customary conditions, including board approval, regulatory compliance and Stock Exchange listing consent, and is targeted for no later than 30 April 2026. If conditions are unmet or unwaived by that date, the agreement will lapse.

Investors are advised that the placement remains conditional and may not proceed until all requirements are satisfied.